NASDAQ$HOLX
Hologic Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Hologic's financial results for Q2 2021 were announced, with revenue increasing by 103.4% and EPS more than quadrupling.
Hologic reported a strong second quarter in fiscal year 2021, with organic revenue doubling due to recovery in base businesses and response to the COVID-19 pandemic. The company completed three acquisitions and announced another, expecting accelerated growth post-pandemic.
- Revenue increased 103.4% for the quarter, or 98.7% in constant currency.
- Organic revenue in the second quarter increased 104.7%, or 100.0% in constant currency.
- Worldwide molecular diagnostics revenue increased 390.6%, or 378.4% in constant currency, driven by demand for SARS-CoV-2 assays.
- Cash flow from operations was $552.3 million, used for acquisitions and repurchase of 1.6 million shares for $120 million.
Headline financials
Revenue & EPS history
Hologic · Revenue · Quarterly
$1.54B
Revenue by segment
Hologic · $2.34B total across 3 segments · Q2 2021
- Diagnostics$1.06B+233.5%45.6%
- Molecular Diagnostics$935M+390.7%40.0%
- Breast Health$336M+9.3%14.4%
Forward guidance
Hologic forecasts strong financial results in Q3 2021, driven by continued strength and recovery in base businesses, partially offset by a potentially conservative outlook for COVID test revenue.
Tailwinds
- Revenue between $1,000 million and $1,070 million
- Reported revenue increase between 21.5% and 30.0%
- Constant Currency revenue increase between 17.9% and 26.4%
- Organic revenue increase between 15.1% and 23.6%
- Non-GAAP EPS between $1.00 and $1.15
Headwinds
- Potentially conservative outlook for COVID test revenue
- Guidance does not include the impact of the pending Mobidiag acquisition
- Based on a non-GAAP tax rate of approximately 21.5%
- Guidance assumes that recent foreign exchange rates persist for all of the third quarter of fiscal 2021
- Organic revenue guidance excludes the divested Blood Screening and the acquired Acessa, Biotheranostics, and Diagenode businesses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.5%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.1%
Avg return
30 days after
49%
35 / 72 earnings
Positive
+12.3%
Q3 2020
Best reaction
-11.4%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.0% | -0.6% | +0.7% | |
| Q4 2025 | +0.1% | +0.1% | +0.9% | |
| Q3 2025 | +2.8% | +4.4% | +3.3% | |
| Q2 2025 | -5.6% | -3.2% | +8.5% | |
| Q1 2025 | -10.1% | -11.4% | -11.3% | |
| Q4 2024 | -4.3% | -4.3% | -6.6% | |
| Q3 2024 | +4.9% | +6.4% | +2.2% | |
| Q2 2024 | +0.3% | -0.2% | -3.3% | |
| Q1 2024 | -2.7% | -0.4% | -1.1% | |
| Q4 2023 | +5.7% | +5.4% | +0.1% | |
| Q3 2023 | -5.1% | -5.9% | -5.4% | |
| Q2 2023 | -2.4% | -2.6% | -8.3% | |
| Q1 2023 | +3.8% | +3.6% | -1.1% | |
| Q4 2022 | +10.8% | +12.4% | +13.8% | |
| Q3 2022 | +1.0% | +1.3% | -3.4% | |
| Q2 2022 | +1.2% | +3.4% | +9.8% | |
| Q1 2022 | +4.0% | +3.8% | +2.4% | |
| Q4 2021 | -3.3% | -5.9% | -0.3% | |
| Q3 2021 | +2.3% | +5.0% | +9.7% | |
| Q2 2021 | -9.1% | -9.9% | -13.4% | |
| Q1 2021 | +1.7% | +11.2% | -3.3% | |
| Q4 2020 | +6.6% | -5.0% | +1.7% | |
| Q3 2020 | +12.3% | +14.8% | -2.8% | |
| Q2 2020 | +2.9% | +2.6% | +8.9% | |
| Q1 2020 | -0.7% | -1.8% | -13.7% | |
| Q4 2019 | -4.0% | +8.8% | +10.3% | |
| Q3 2019 | -1.3% | -6.5% | -4.1% | |
| Q2 2019 | -0.1% | +0.7% | -5.1% | |
| Q1 2019 | +0.6% | -0.5% | +8.6% | |
| Q4 2018 | +4.9% | +1.2% | +3.7% | |
| Q3 2018 | -3.5% | -1.9% | -7.5% | |
| Q2 2018 | -6.9% | -6.8% | -3.9% | |
| Q1 2018 | -6.7% | -6.6% | -2.2% | |
| Q4 2017 | +0.4% | +2.9% | +8.1% | |
| Q3 2017 | -9.3% | -11.3% | -12.5% | |
| Q2 2017 | -4.3% | -5.1% | -2.0% | |
| Q1 2017 | -2.6% | -2.9% | +1.8% | |
| Q4 2016 | +4.3% | +8.5% | +6.3% | |
| Q3 2016 | +3.9% | +5.8% | +5.3% | |
| Q2 2016 | -10.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +8.6% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | +5.1% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | +8.1% | — | — | |
| Q1 2014 | -5.9% | — | — | |
| Q4 2013 | -6.9% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -11.4% | — | — | |
| Q1 2012 | +5.2% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q3 2011 | -3.9% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q2 2009 | +2.9% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q4 2009 | +2.9% | — | — | |
| Q3 2009 | -3.0% | — | — | |
| Q3 2008 | -3.0% | — | — | |
| Q4 2008 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro